Quell Therapeutics

Today, we are announcing that we have achieved the first significant milestone from our strategic collaboration with AstraZeneca: the selection and licensing of a CAR-Treg candidate from our Type 1 Diabetes (T1D) program that AstraZeneca will now further develop into the clinic with Quell’s continued participation including product supply for first-in-human trials.   Achieving this milestone triggers an option exercise payment of $10 million to Quell.   The nomination of this first T1D CAR-Treg candidate complements the advances we are making with QEL-001, our internal program in transplantation, and demonstrates the potential of our powerful technology to unlock a broad opportunity across autoimmune and inflammatory diseases.   #Innovation #Biotech #Collaboration #Milestone #LifeSciences

It was an exciting day at Quell Therapeutics yesterday as our CEO Iain McGill and the team welcomed Rt Hon Rachel Reeves, Chancellor of the Exchequer, to the Translation & Innovation Hub in London where she opened our newly refurbished offices.   She was accompanied by Emma Reynolds (Minister for Pensions), Steve Bates OBE FMedSci (CEO of the UK Bioindustry Association, BIA) and Kristen McLeod CBE (CSO of the British Business Bank). After meeting Quell employees and a tour of our state-of-the-art lab facilities, Ms. Reeves was interviewed by the BBC, Financial Times and Bloomberg, where she shared insights on the UK Government’s vision for pension “megafunds” to accelerate growth of the UK economy and particularly investment into innovative sectors that capitalise on the UK’s world-leading research capabilities.   At Quell, we share Ms. Reeves’ commitment to unlocking funding and fostering a vibrant UK life sciences ecosystem that supports our ambitions to build Quell into a meaningful and successful UK biopharma business.   https://lnkd.in/dNqicSsN? https://lnkd.in/eU66NzfX https://lnkd.in/dZkU5axN   #LifeSciences #Innovation #UKBiotech #Investment #MansionHouseReforms #HealthcareInnovation

We are excited to share more data from our Treg cell therapy platform at European Society of Gene and Cell Therapy (ESGCT) congress in Rome this week, and also at American Association for the Study of Liver Diseases (AASLD) 'The Liver Meeting' in San Diego in November. These data presentations include further findings from the safety cohort of our QEL-001 Phase 1/2 LIBERATE study in Liver Transplantation, as well as the first disclosure of data from our iPSC-Treg allogeneic platform. Details of the presentations via the link below. #ESGCT2024 #AASLD2024 #TheLiverMeeting

Quell is pleased to announce a new partnership with @eXmoor pharma to provide increased manufacturing capacity for our advancing pipeline of autologous engineered CAR-Treg cell therapy product candidates targeting autoimmune diseases. We look forward to building on our long-standing relationship with eXmoor to advance multiple CAR-Treg candidates into clinical development, and benefitting from eXmoor’s expertise and its new, state-of-the-art Cell & Gene Therapy Centre in Bristol, UK.

We are pleased to welcome Luke Beshar as Chair of Quell’s Board of Directors.   Luke brings more than 35 years of strategic development, financial and transactional experience to Quell from his Board and C- suite executive roles at several innovative, high-growth public and private companies. This experience will be crucial as we prepare for first efficacy readouts from our LIBERATE study and execute our strategy to build a truly world-class company.   Read the full press release: https://lnkd.in/efpcyuQ2   #tregs #Hepatology #Immunosuppression

We are delighted to announce that QEL-001, Quell Tx’s multi-modular engineered CAR-Treg cell therapy, is being advanced into the efficacy cohort of the LIBERATE Phase 1/2 trial in liver transplant patients. A trial progress update was presented today at the American Transplant Congress in Philadelphia, PA, USA.   We look forward to entering the next phase of this clinical trial, which has been designed to test a new, potentially transformational paradigm for liver transplant patients.   Find out more: https://lnkd.in/ekQeuEy4   #Immunosuppression #Hepatology #ATC2024

This week our team are in Vancouver for #ISCT2024. Our SVP Research & Product Development Nathalie Belmonte will be giving a presentation tomorrow (31st May) discussing how we are using CAR-Tregs to treat autoimmune diseases. Yesterday, Sim Tung presented a poster on our technology platform, and Aleks Guvenel, shared his insights on a panel re: next gen manufacturing platforms. Great to see our R&D team presenting our science to the global cell therapy community!

This week our team are in Vancouver for #ISCT2024. Our SVP Research & Product Development Nathalie Belmonte will be giving a presentation tomorrow (31st May) discussing how we are using CAR-Tregs to treat autoimmune diseases. Yesterday, Sim Tung presented a poster on our technology platform, and Aleks Guvenel, shared his insights on a panel re: next gen manufacturing platforms. Great to see our R&D team presenting our science to the global cell therapy community!

Our team are excited to be coming together with the Treg community this week at the 6th Annual Treg Summit in Boston. Our CMO Luke Devey will be joining a panel discussion today (May 22) and our VP Biology Marc Martinez-Llordella will be presenting an update on Quell’ scientific progress tomorrow (May 23). #CARTregs

Our team had a fantastic week at ASGCT conference in Baltimore - we had a great reception from the community to our CAR-TReg science, and came away with lots of new ideas to further build our platform forward to create transformative therapies for patients. Bravo!